Search Results
Your search for Michael Wang, MD,Michael Wang, MD matches 44 pages
Showing 1 - 44In Case You Missed It: Roundup From ESMO Congress 2024
In addition to our in-depth analysis of important clinical trials presented at the European Society for Medical Oncology (ESMO) Congress 2024, there is always room for more coverage from The ASCO Post, including these brief summaries of other presentations of interest. They focus on a potential...
Acalabrutinib Plus Chemoimmunotherapy Improves Progression-Free Survival in Older Patients With Mantle Cell Lymphoma
Combining Bruton’s tyrosine kinase (BTK) inhibition with chemoimmunotherapy induction significantly extended progression-free survival for older patients with mantle cell lymphoma, and there was also a trend toward improvement on the overall survival benefit, according to data presented during the...
A Daughter of First-Generation Immigrants Follows Their Can-Do Philosophy in Her Research Efforts in Hematologic Oncology
Leukemia expert Eunice S. Wang, MD, is the daughter of first-generation immigrants, whose work ethos inspired in her a world without boundaries. “My parents were born in China during the communist era, and they immigrated to Taiwan when the communists took over in the 1940s and then subsequently...
Narratives in Oncology Through the Years
Beginning in 2012, The ASCO Post introduced Narratives in Oncology, a special commemorative issue profiling several of the many leaders in the oncology community. Over the past dozen years, many in the oncology community have been profiled in this special issue. A complete list of individuals...
SYMPATICO Trial: Ibrutinib Plus Venetoclax Improves Progression-Free Survival in Relapsed Mantle Cell Lymphoma
The combination of ibrutinib and venetoclax has led to an improved progression-free survival rate in patients with relapsed or refractory mantle cell lymphoma (MCL), according to findings presented at the 2023 American Society of Hematology (ASH) Annual Meeting & Exposition.1 Interim analysis...
Michael Wang, MD, on Mantle Cell Lymphoma: New Results on Ibrutinib Plus Venetoclax
Michael Wang, MD, of The University of Texas MD Anderson Cancer Center, discusses phase III results from the Sympatico study, which shows the combination of ibrutinib and venetoclax improved progression-free survival vs ibrutinib plus placebo in patients with relapsed or refractory mantle cell...
Ibrutinib/Venetoclax in Relapsed/Refractory Mantle Cell Lymphoma
Patients with relapsed or refractory mantle cell lymphoma who received ibrutinib in combination with venetoclax experienced significantly better rates of progression-free survival compared with patients who received ibrutinib and placebo, according to findings from the international phase III...
Noncovalent BTK Inhibitor Pirtobrutinib in Patients With Mantle Cell Lymphoma Previously Treated With Covalent BTK Inhibitors
In the phase I/II BRUIN trial reported in the Journal of Clinical Oncology, Michael Wang, MD, and colleagues found that the noncovalent (reversible) Bruton’s tyrosine kinase (BTK) inhibitor pirtobrutinib produced durable responses in patients with mantle cell lymphoma who were previously treated...
Brexucabtagene Autoleucel in Relapsed or Refractory Mantle Cell Lymphoma in Standard-of-Care Practice
In an analysis from the U.S. Lymphoma CAR T Consortium reported in the Journal of Clinical Oncology, Wang et al found that standard-of-care treatment with brexucabtagene autoleucel in relapsed or refractory mantle cell lymphoma since its approval in this setting has been associated with response...
Andrew D. Zelenetz, MD, PhD, and Michael L. Wang, MD, on Mantle Cell Lymphoma: New Data on Ibrutinib in Combination With Bendamustine/Rituximab and Rituximab Maintenance
Andrew D. Zelenetz, MD, PhD, of Memorial Sloan Kettering Cancer Center, and Michael L. Wang, MD, of The University of Texas MD Anderson Cancer Center, discuss primary results from the phase III SHINE study, which showed that ibrutinib, in combination with bendamustine/rituximab and rituximab...
Brexucabtagene Autoleucel in Relapsed or Refractory Mantle Cell Lymphoma: 3-Year Follow-up of ZUMA-2 Trial
In an analysis presented at the 2022 ASCO Annual Meeting (Abstract 7518) and simultaneously reported in the Journal of Clinical Oncology, Michael Wang, MD, and colleagues provided data from the 3-year follow-up of the pivotal ZUMA-2 trial of the chimeric antigen receptor (CAR) T-cell therapy...
Ibrutinib Added to Standard Therapy Prolongs Progression-Free Survival in Older Patients With Mantle Cell Lymphoma
Primary results from the phase III SHINE trial demonstrated that first-line treatment with ibrutinib combined with bendamustine/rituximab and rituximab maintenance achieves a substantial prolongation of progression-free survival in elderly patients with mantle cell lymphoma, according to a...
PD-1 Inhibition in First-Line Treatment of Advanced Esophageal Squamous Cell Carcinoma: More to Come on New Paradigm
Esophageal cancer is associated with significant morbidity and mortality worldwide, with more than 600,000 new cases and 540,000 deaths in 2020. The squamous cell histology comprises nearly 90% of cases globally, despite its steady decline in the United States over the past 40 years. Historically,...
Mantle Cell Lymphoma Previously Treated With BTK Inhibitor May Respond to a Newer BTK Inhibitor
The next-generation inhibitor of Bruton’s tyrosine kinase (BTK) may be effective in mantle cell lymphoma for patients previously treated with an older BTK inhibitor, according to results from the phase I/II BRUIN trial. These findings were reported at the 2021 American Society of Hematology (ASH)...
Ibrutinib/Rituximab Induction Followed by R-HCVAD in Front-Line Treatment of Patients Aged 65 and Younger With Mantle Cell Lymphoma
In the single-institution phase II WINDOW-1 trial reported in The Lancet Oncology, Michael L. Wang, MD, and colleagues found that 12 cycles of induction ibrutinib/rituximab produced objective response in nearly all patients aged ≤ 65 years with mantle cell lymphoma, allowing a reduction in cycles...
First-Line Ibrutinib/Rituximab in Patients With Mantle Cell Lymphoma Aged 65 and Older
In a single-institution phase II trial reported in the Journal of Clinical Oncology, Jain et al found that chemotherapy-free treatment with the combination of ibrutinib and rituximab produced high overall and complete response rates in patients with previously untreated mantle cell lymphoma aged ≥...
Overcoming the Disparities in Cancer Survival Among AYA Minority Patients
Although the National Cancer Institute (NCI) has identified adolescents and young adults (AYAs) with cancer as a distinct patient population from children and older adults with the disease, research into the diagnosis, treatment, and survivorship specific to this patient population has not kept...
Noncovalent BTK Inhibitor Pirtobrutinib in Relapsed or Refractory B-Cell Malignancies
In the phase I/II BRUIN trial reported in The Lancet, Anthony R. Mato, MD, and colleagues found that the noncovalent Bruton’s tyrosine kinase (BTK) inhibitor pirtobrutinib produced durable responses in patients with relapsed or refractory B-cell malignancies, including those previously treated with ...
Identifying Characteristics of Infused CAR T Cells Associated With Efficacy and Toxicity in Patients With Large B-Cell Lymphoma
Researchers have identified molecular and cellular characteristics of anti-CD19 chimeric antigen receptor (CAR) T-cell infusion products associated with how patients with large B-cell lymphoma respond to treatment and develop side effects. The research team also found that early changes in...
Leaders in Radiation Oncology Awarded ASTRO Fellow Designation
The American Society for Radiation Oncology (ASTRO) has selected 19 distinguished members to receive the ASTRO Fellow (FASTRO) designation. The 2020 class of Fellows will be recognized at a virtual awards ceremony on October 27 during ASTRO’s 62nd Annual Meeting. The ASTRO Fellows program...
PD-1 Inhibition in Mismatch Repair–Deficient/Microsatellite Instability–High Cancers Other Than Colorectal Cancer
Mismatch repair (MMR)-deficiency and consequently high DNA microsatellite instability (MSI-H) are associated with high tumor mutational burden. A high mutational load increases the potential number of neoantigens that can be presented by the tumor cell and recognized by host lymphocytes. Detection...
KTE-X19 for Relapsed or Refractory Mantle Cell Lymphoma: ZUMA-2 Trial
In a phase II trial reported in The New England Journal of Medicine, Michael Wang, MD, and colleagues found that the anti-CD19 chimeric antigen receptor (CAR) T-cell therapy KTE-X19 produced a high response rate in patients with relapsed or refractory mantle cell lymphoma who had received previous...
CAR T-Cell Therapy Comes to Mantle Cell Lymphoma
Advanced mantle cell lymphoma appears to be a good target for chimeric antigen receptor (CAR) T-cell therapy. Treatment with KTE-X19, an anti-CD19 CAR T-cell product, led to unprecedented outcomes in patients with relapsed or refractory disease in the phase II ZUMA-2 study presented at the 2019 ASH ...
Actively Recruiting Clinical Trials Focused on Survivorship
This Clinical Trials Resource Guide lists actively recruiting clinical research trials that focus on cancer survivorship. The studies here are examining the effects of Web-based platforms, as well as patient navigators and other tools. and the value of improving our understanding of the...
Conquer Cancer Honors Oncology Professionals With Merit Awards at the 2019 ASCO Annual Meeting
Conquer Cancer®, the ASCO Foundation, is pleased to announce the recipients of its 2019 ASCO Annual Meeting Merit Awards. These distinguished awards support oncology trainees who were first authors on abstracts selected for presentation at the ASCO Annual Meeting. This year, Conquer Cancer...
Treatment-Related Adverse Events With PD-1/PD-L1 Inhibitors in Clinical Trials
In a systematic review and meta-analysis reported in JAMA Oncology, Wang et al characterized treatment-related adverse event profiles associated with monotherapy use of programmed cell death protein 1 (PD-1) and programmed cell death ligand 1 (PD-L1) inhibitors in clinical trials. Study Details...
Highlights From the 2018 ASH Annual Meeting & Exposition
TO ADD to our ongoing coverage of the 2018 American Society of Hematology (ASH) Annual Meeting & Exposition, we bring readers of The ASCO Post these summaries of an assortment of interesting studies. They focus on novel therapies under investigation in the treatment of acute lymphoblastic...
ASCO Annual Meeting Merit Awards: This Year’s Winners
The Conquer Cancer Merit Awards support oncology trainees who are first authors on abstracts selected for presentation at an ASCO scientific meeting, including the ASCO Annual Meeting and thematic symposia. Conquer Cancer recognized 127 recipients with Merit Awards at the 2018 ASCO Annual Meeting,...
Tai Chi for the Treatment of Insomnia in Breast Cancer Survivors
Underrecognized and inadequately managed, insomnia is a significant burden for many cancer survivors. Often persistent over several years following diagnosis and treatment, sleep problems negatively affect quality of life and elevate the risk of depression and anxiety. In this installment of The...
AACR 2018: Short-Acting Calcium Channel Blockers Associated With Increased Risk of Pancreatic Cancer in Postmenopausal Women
Calcium channel blockers (CCBs)—specifically the short-acting form of CCBs, which are prescribed to treat high blood pressure—were associated with an increased risk of pancreatic cancer in postmenopausal women, according to a study presented at the American Assocation for Cancer...
BTK Inhibitor in Relapsed or Refractory Mantle Cell Lymphoma
A phase II study (ACE-LY-004) reported in The Lancet by Michael Wang, MD, of The University of Texas MD Anderson Cancer Center, and colleagues showed durable responses with the Bruton tyrosine kinase inhibitor acalabrutinib (Calquence) in patients with relapsed or refractory mantle cell lymphoma....
Bruton Tyrosine Kinase Inhibitor in Relapsed or Refractory Mantle Cell Lymphoma
A phase II study (ACE-LY-004) reported in The Lancet by Michael Wang, MD, of The University of Texas MD Anderson Cancer Center, and colleagues showed durable responses with the Bruton tyrosine kinase inhibitor acalabrutinib (Calquence) in patients with relapsed or refractory mantle cell lymphoma....
BTK Inhibitor in Relapsed or Refractory Mantle Cell Lymphoma
A phase II study (ACE-LY-004) reported in The Lancet by Wang et al showed durable responses with the Bruton tyrosine kinase inhibitor acalabrutinib (Calquence) in patients with relapsed or refractory mantle cell lymphoma. The study supported the recent approval of acalabrutinib in this setting....
ASH 2017: Acalabrutinib Demonstrates Activity in Relapsed or Refractory Mantle Cell Lymphoma
At the 59th American Society of Hematology (ASH) Annual Meeting & Exposition, Wang et al presented results from the open-label, single-arm phase II ACE-LY-004 clinical trial, which served as the basis for the recent U.S. Food and Drug Administration (FDA) accelerated approval of acalabrutinib...
ASCO, Conquer Cancer Foundation Congratulate 2016 Grant and Award Recipients
The Conquer Cancer Foundation of ASCO (CCF) presented more than $6.1 million in grants and awards to nearly 250 promising oncology researchers at the 2016 ASCO Annual Meeting. The Conquer Cancer Foundation and ASCO congratulate the recipients on their contributions to the field of oncology and...
New Analysis Evaluates Predictors of Persistent Pain After Breast Cancer Surgery
An analysis led by McMaster University researchers has found that women who undergo armpit lymph node surgery for breast cancer are much more likely to develop chronic pain. Wang et al published their review of studies exploring risk factors for developing chronic pain after breast cancer...
Conquer Cancer Foundation Honors 74 Oncologists for Contributions to Genitourinary Cancer, Cancer Survivorship, Gastrointestinal Cancer, and Quality Care Research
The Conquer Cancer Foundation of ASCO is pleased to announce the recipients of its 2016 Conquer Cancer Foundation of ASCO Merit Awards in Gastrointestinal Cancer, Genitourinary Cancer, Cancer Survivorship, and Quality Care. The following 74 young investigators, recognized for the scientific merit...
Winning the Battle at the Front Lines: Lenalidomide Plus Rituximab— A Promising Initial Treatment for Mantle Cell Lymphoma
Mantle cell lymphoma is a pernicious, incurable disease. Front-line therapies for this disease are not currently standardized; however, novel therapies for relapsed or refractory mantle cell lymphoma can ideally be translated into beneficial treatments for newly diagnosed patients, as clearly...
Lenalidomide Plus Rituximab Highly Active in Initial Treatment of Mantle Cell Lymphoma
In a phase II trial reported in The New England Journal of Medicine by Jia Ruan, MD, PhD, and colleagues, first-line treatment with the immunomodulatory agent lenalidomide (Revlimid) and the anti-CD20 antibody rituximab (Rituxan) followed by maintenance lenalidomide and rituximab produced a high...
Ibrutinib in Mantle Cell Lymphoma Yields 'Unprecedented' Response Rates
The investigational agent ibrutinib demonstrated “unprecedented” single-agent activity in relapsed or refractory mantle cell lymphoma, according to the lead author of an international phase II study reported at the Annual Meeting of the American Society of Hematology (ASH).1 Durable Responses “The...
Ibrutinib Produces High Response Rate in Patients with Refractory Mantle Cell Lymphoma
Ibrutinib is a first-in-class oral covalent inhibitor of Bruton’s tyrosine kinase, a mediator of the B cell-receptor signaling pathway implicated in the pathogenesis of B-cell cancers. As reported in The New England Journal of Medicine, Michael L. Wang, MD, of The University of Texas MD Anderson...
Residents Association Recognizes 57 Mentors and Teachers With 2014 Educator of the Year Award
The Association of Residents in Radiation Oncology (ARRO) has honored 57 educators with the 2014 Educator of the Year Award. The award, presented annually, recognizes outstanding teachers and mentors of radiation oncology residents. Each radiation oncology residency program may nominate one faculty ...
Oncologists Encouraged to Learn More About Lesser-Known Heritable Gastrointestinal Cancers
The genetic basis for inherited colorectal cancer is proving to be a much bigger and more complicated “pie” than was appreciated just a few years ago, according to Michael Hall, MD, Director of Gastrointestinal Risk Assessment at Fox Chase Cancer Center, Philadelphia. “With next-generation...
BTK Inhibitor Ibrutinib Produces High Response Rate in Relapsed/Refractory Mantle Cell Lymphoma
Ibrutinib is a first-in-class oral covalent inhibitor of Bruton’s tyrosine kinase (BTK), a mediator of the B-cell receptor signaling pathway implicated in the pathogenesis of B-cell cancers. As reported in The New England Journal of Medicine, Michael L. Wang, MD, of The University...
